Clinical Trial Update: Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating postoperative hypofractionated radiation therapy combined with an LHRH agonist for prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• LHRH agonist (Gonadotropin-releasing hormone (GnRH) agonist)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING